(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 June 2015 (11.06.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/084736 A2

(51) International Patent Classification:
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2014/067957

(22) International Filing Date:
1 December 2014 (01.12.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/911,186 3 December 2013 (03.12.2013) US

(71) Applicant: **WELT BIO-MOLECULAR PHARMACEUTICAL, LLC** [US/US]; 59 Whippoorwill Crossing, Armonk, NY 10504 (US).

(72) Inventor; and
(71) Applicant : **WELT, Sydney** [US/US]; 59 Whippoorwill Crossing, Armonk, NY 10504 (US).

(72) Inventors: **KOSTYAL, David**; 2887 Gilchrist Rd., Akron, OH 44305-4415 (US). **WELT, Rachel, S.**; 59 Whippoorwill Crossing, Armonk, NY 10504 (US). **RAYMOND, Virginia**; 59 Whippoorwill Crossing, Armonk, NY 10504 (US). **WELT, Jonathan, A.**; 59 Whippoorwill Crossing, Armonk, NY 10504 (US).

(74) Agents: **BARNHARD, Elizabeth** et al.; Leason Ellis LLP, One Barker Avenue, Fifth Floor, White Plains, NY 10601 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: ANTIBODIES TARGETING B-CELL RECEPTOR COMPLEX MEMBRANE BOUND IGM AND USES THEREOF

(57) Abstract: The present invention relates to antibodies targeting the membrane bound IgM (mIgM) of the B-cell receptor complex found in B-cell lymphomas and leukemias and uses thereof. Another aspect of the present invention is the use of anti-B-Cell mIgM antibodies in the treatment of Be-cell malignancies, including B-cell lymphomas and leukemias.




FIG.1A




FIG.1B




FIG.1C




FIG.1D

WO 2015/084736 A2

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

— *with sequence listing part of description (Rule 5.2(a))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*